News Column

'Nanodaisies' Deliver Drug Cocktail to Cancer Cells

May 28, 2014



Biomedical engineering researchers have developed daisy-shaped, nanoscale structures that are made predominantly of anti-cancer drugs and are capable of introducing a "cocktail" of multiple drugs into cancer cells. The researchers are all part the joint biomedical engineering program at North Carolina State University and the University of North Carolina at Chapel Hill.

Early tests of the "nanodaisy" drug delivery technique show promise against a number of cancers. Image credit: Ran Mo. Click to enlarge.

"We found that this technique was much better than conventional drug-delivery techniques at inhibiting the growth of lung cancer tumors in mice," says Dr. Zhen Gu, senior author of the paper and an assistant professor in the joint biomedical engineering program. "And based on in vitro tests in nine different cell lines, the technique is also promising for use against leukemia, breast, prostate, liver, ovarian and brain cancers."

To make the "nanodaisies," the researchers begin with a solution that contains a polymer called polyethylene glycol (PEG). The PEG forms long strands that have much shorter strands branching off to either side. Researchers directly link the anti-cancer drug camptothecin (CPT) onto the shorter strands and introduce the anti-cancer drug doxorubicin (Dox) into the solution.

PEG is hydrophilic, meaning it likes water. CPT and Dox are hydrophobic, meaning they don't like water. As a result, the CPT and Dox cluster together in the solution, wrapping the PEG around themselves. This results in a daisy-shaped drug cocktail, only 50 nanometers in diameter, which can be injected into a cancer patient.

Once injected, the nanodaisies float through the bloodstream until they are absorbed by cancer cells. In fact, one of the reasons the researchers chose to use PEG is because it has chemical properties that prolong the life of the drugs in the bloodstream.

Once in a cancer cell, the drugs are released. "Both drugs attack the cell's nucleus, but via different mechanisms," says Dr. Wanyi Tai, lead author and a former postdoctoral researcher in Gu's lab.

"Combined, the drugs are more effective than either drug is by itself," Gu says. "We are very optimistic about this technique and are hoping to begin pre-clinical testing in the near future."

The paper, " Folding Graft Copolymer with Pedant Drug Segment for Co-Delivery of Anticancer Drugs ," is published online in the journal Biomaterials . Co-authors include Dr. Ran Mo, a current postdoctoral researcher in the program, and Yue Lu and Tianyue Jiang, who are both Ph.D. students in the program. The research was supported by the National Institutes of Health under grant 1UL1TR001111 and funding from NC State and UNC-Chapel Hill.

-shipman-

Note to Editors: The study abstract follows.

"Folding Graft Copolymer with Pedant Drug Segment for Co-Delivery of Anticancer Drugs"

Authors : Wanyi Tai, Ran Mo, Yue Lu, Tianyue Jiang, and Zhen Gu, North Carolina State University and University of North Carolina at Chapel Hill

Published : May 27, 2014, Biomaterials

Abstract: A graft copolymer with pendant drug segment can fold into nanostructures in a "protein folding-like" manner. The graft copolymer is constructed by directly polymerizing ?-camptothecin-glutamate N-carboxyanhydride (Glu(CPT)-NCA) on multiple sites of poly(ethylene glycol) (PEG)-based main chain via the ring open polymerization. The "purely" conjugated anticancer agent camptothecin (CPT) is hydrophobic and serves as the principal driving force during the folding process. When exposed to water, the obtained copolymer, together with doxorubicin (Dox), another anticancer agent, can fold into uniform nanocarriers for dual-drug delivery. Equipped with a PEG shell, the nanocarriers displayed good stability and can be internalized by a variety of cancer cell lines via the lipid raft and clathrin-mediated endocytotic pathway without premature leakage, which showed a high synergetic activity of CPT and Dox toward various cancer cells.In vivo study validated that the nanocarriers exhibited strong accumulation in tumor sites and showed a prominent anticancer activity against the lung cancer xenograft mice model compared with free drugs.

Dr. Zhen Gu

Tel: +1 919 515 7944

.


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: M2 PressWIRE


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters